Department of Neurological Surgery, Oregon Health & Science University, Mail Code CH8N, 3303 South Bond Ave, Portland, OR, 97239, USA.
Pituitary Center, Oregon Health & Science University, Mail Code CH8N, 3303 South Bond Ave, Portland, OR, 97239, USA.
J Endocrinol Invest. 2021 Dec;44(12):2665-2674. doi: 10.1007/s40618-021-01579-4. Epub 2021 Apr 24.
Acromegaly is a rare disease and is associated with increased cardiovascular (CV) morbidity and mortality, especially in patients with uncontrolled disease. We aimed to analyze the prevalence and severity of cardiomyopathy and valvular heart disease in a large cohort of patients with a confirmed acromegaly diagnosis, at baseline and after treatment.
We retrospectively reviewed an institutional approved database; 190 patients with confirmed acromegaly and follow-up data available (years 2006-2018). Patients with at least one baseline echocardiogram, were included. Demographic, disease control and echocardiogram variables were collected for analysis.
Of the 190 patients 110 (58%) had a baseline echocardiogram and 43 (39.1%) had at least one follow-up echocardiogram after surgical, medical or multimodal treatment. Baseline left ventricular hypertrophy (LVH) prevalence was 17.8% (64.7% concentric; 35.3% eccentric), diastolic and systolic dysfunction, and overt cardiomyopathy with heart failure were 15.8, 7.9, and 3.0%, respectively. Concentric remodeling of the left ventricle (LV) was noted in 31.4% of patients without LVH. Valve defects were found in 87.3% of patients (14.6% with significant valvular heart disease).
Early diagnosis of acromegaly and disease control should be attempted to prevent LVH/LV dysfunction and development of valvular heart disease. Concentric LV remodeling develops prior to obvious LV hypertrophy in almost a third of patients with acromegaly, which is a novel finding. Similar to other epidemiological studies, we found a high prevalence of LVH/LV dysfunction. Although possible, reversal of systolic and diastolic dysfunction is sporadic after treatment of acromegaly.
肢端肥大症是一种罕见的疾病,与心血管(CV)发病率和死亡率增加有关,尤其是在疾病未得到控制的患者中。我们旨在分析大量确诊肢端肥大症患者在基线和治疗后的心肌病和心脏瓣膜病的患病率和严重程度。
我们回顾性审查了一个机构批准的数据库;共纳入 190 例确诊肢端肥大症且有随访数据的患者(2006 年至 2018 年)。纳入至少有一次基线超声心动图的患者。收集人口统计学、疾病控制和超声心动图变量进行分析。
在 190 例患者中,有 110 例(58%)有基线超声心动图,43 例(39.1%)在接受手术、药物或多模式治疗后至少有一次随访超声心动图。基线左心室肥厚(LVH)患病率为 17.8%(64.7%为向心性;35.3%为离心性),舒张和收缩功能障碍以及明显的心力衰竭性心肌病的患病率分别为 15.8%、7.9%和 3.0%。无 LVH 的患者中有 31.4%存在左心室(LV)同心性重构。发现 87.3%的患者存在瓣膜缺陷(14.6%有明显的心脏瓣膜病)。
应尝试早期诊断肢端肥大症并控制疾病,以预防 LVH/LV 功能障碍和心脏瓣膜病的发生。在近三分之一的肢端肥大症患者中,LVH 之前会发生左心室同心性重构,这是一个新发现。与其他流行病学研究一样,我们发现 LVH/LV 功能障碍的患病率很高。尽管可能,但在治疗肢端肥大症后,收缩和舒张功能障碍的逆转是零星的。